weight loss drugs

Patients

A new GLP-1 opportunity for pharma: Supporting patients’ emo...

People with obesity in Western cultures have largely been subject to shame, blame, stigma, and discrimination that condemns them for their current situation while simultaneously scorning th

R&D

Weight loss gold rush: Developers vie for next blockbuster t...

Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and Novo Nordisk’s therapies.

Market Access

Weight loss treatments bring in billions but capacity remain...

The high demand for weight loss treatments has made their rollout a staggered process.

R&D

The race for obesity drug assets heats up

The existing treatments for weight loss have drawn interest from across the industry, as their efficacy and sales potential become evident.

Patients

Why medical weight loss is more complicated than GLP-1s

A few weeks ago on the pharmaphorum podcast, we discussed the new GLP-1 weight loss drugs and their shake-up effect on the medical weight loss industry.

R&D